GlaxoSmithKline (GSK) has come out with a ton of information that say its diabetes drug Avandia is safe for the heart.
Big companies seem to be masters of releasing key information late, especially when they are attacked.
The drug was savaged in a recent article in The New England Journal of Medicine. The piece said that avandia could increase the risk of heart attack. And, apparently, use of the drug has dropped sharply in the US after the study came out. Volunteers have even been dropping out of the GSK study, probably due to concerns about the potential dangerous side-effects.
It is a wonder that the Glaxo information was not made available to doctors and patients before the negative press came out. Perhaps someone left the positive study in a drawer..
Douglas A. McIntyre can be reached at [email protected]. He does now own own securities in companies that he writes about.
Top Gaining Stocks
Top Losing Stocks